alipogene tiparvovec + Prednisolone + Cyclosporins + Mycophenolate mofetil
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
LPL Deficiency
Conditions
LPL Deficiency
Trial Timeline
Oct 1, 2016 → Sep 1, 2020
NCT ID
NCT02904772About alipogene tiparvovec + Prednisolone + Cyclosporins + Mycophenolate mofetil
alipogene tiparvovec + Prednisolone + Cyclosporins + Mycophenolate mofetil is a phase 2 stage product being developed by uniQure for LPL Deficiency. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT02904772. Target conditions include LPL Deficiency.
What happened to similar drugs?
8 of 20 similar drugs in LPL Deficiency were approved
Approved (8) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
12
Activity
0
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02904772 | Phase 2 | Withdrawn |
Competing Products
20 competing products in LPL Deficiency